What is GHRS (GHRS) stock price today?

GHRS (GHRS) is currently trading at $29.10, down 0.06% today.

What is GHRS P/E ratio?

GHRS's P/E ratio is -10.34. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GHRS return on equity (ROE)?

GHRS's return on equity (ROE) is -19.67%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is GHRS's market cap?

GHRS has a market capitalization of $2.00B.

NASDAQ · Biotechnology

GHRS (GHRS) Stock

$29.10 -0.06% NASDAQ: GHRS Healthcare

Valuation

Metric	Value
Price	$29.10
Market Cap	$2.00B
P/E Ratio	-10.34
P/B Ratio	4.87
P/S Ratio	0.00
EPS (TTM)	$-0.79
52-Week High	$30.25
52-Week Low	$11.32
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-19.67%
ROA	-13.99%
ROCE	-21.86%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	35.75

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-15.0M	$-31.0M	$-41.0M	$-50.0M	$-61.0M
Net Profit	$-9.0M	$-22.0M	$-36.0M	$-39.0M	$-48.0M
EPS	$-0.18	$-0.14	$-0.68	$-0.75	$-0.79
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$280.0M	$254.0M	$226.0M	$188.0M	$288.0M
Total Liabilities	$3.0M	$5.0M	$7.0M	$9.0M	$9.0M
Cash	$277.0M	$166.0M	$78.0M	$101.0M	$246.0M
Borrowings	$0	$0	$1.0M	$1.0M	$1.0M

Latest News

The Race to Commercialize the World’s Most Powerful Psychedelic WSJ · Jul 14, 2026 Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says Proactive · Jul 13, 2026 Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026? Zacks · Jul 2, 2026 AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs Zacks · Jul 2, 2026 AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 Zacks · Jul 2, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-15.0M	$-26.0M	$-33.0M	$-42.0M	$-44.0M
Investing Cash Flow	$0	$-85.0M	$-54.0M	$65.0M	$46.0M
Financing Cash Flow	$-23.0M	$0	$0	$0	$0
Net Cash Flow	$271.0M	$-111.0M	$-88.0M	$22.0M	$145.0M
Free Cash Flow	$-15.0M	$-26.0M	$-33.0M	$-42.0M	$-44.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	-15.67
FCF Yield	-3.28%
Quick Ratio	23.04
Interest Coverage	—
Return 1Y	71.24%
Return 3Y	118.17%
Return 5Y	65.11%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ABUS	$4.41	+0.00%	-25.41	$871.14M	0.00%
KURA	$9.57	+3.13%	-2.90	$849.57M	0.00%
LENZ	$5.05	+1.10%	-3.18	$158.34M	0.00%
NBTXNanobiotix S.A.	$40.18	+1.21%	-68.71	$2.03B	0.00%
PROKProKidney Corp.	$1.56	+3.67%	-2.73	$522.87M	0.00%

About GHRS

GHRS is led by CEO Velichka Valcheva, employs 50 people, headquartered in IE, publicly traded since 2021.

GHRS stock trades at $29.10 with a market capitalization of $2.00B. The stock is valued at a price-to-earnings (P/E) ratio of -10.34, price-to-book of 4.87, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $11.32 and $30.25, and currently trades 3.8% below its 52-week high.

On profitability, GHRS generates a return on equity (ROE) of -19.67%, return on capital employed of -21.86%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides